ViiV HEALTHCARE STATEMENT ON COMPULSORY LICENCE FOR DOLUTEGRAVIR IN COLOMBIA
25th April 2024
ViiV Healthcare is committed to enabling access to our medicines to benefit people living with HIV, regardless of income or where they live.
The Colombian Superintendency of Industry and Commerce (the Colombian Patent Office) has granted a compulsory licence to dolutegravir for governmental use.
We have been in dialogue with the Colombian government through the process to understand its situation in more detail, in particular the effects of the Venezuelan migrant crisis on the Colombian healthcare system, and to find a solution. Therefore, we are disappointed by this decision, despite our best efforts to put proposals forward that achieve the Government’s public health objectives as set out in the Declaration of Public Interest without recourse to a compulsory licence.
We do not consider that compulsory licences are an effective means to support sustainable access or increase access to innovative medicines and have a detrimental impact around confidence in trade. The use of compulsory licences weakens the intellectual property system relied on by the life sciences sector to conduct the innovative and costly research and development necessary to drive advances in HIV treatment and care. As well as discouraging innovation, compulsory licensing seeks to push the costs of developing new medicines onto other countries.
We have made submissions opposing the grant of the compulsory licence throughout the process, and we will continue to oppose going forward, using appropriate legal means in Colombia and the Andean Community, and those available under international treaties.
We remain open to engage with the Colombian government to find a solution and will continue to provide a consistent supply of dolutegravir in Colombia, as we have been doing since the medicine was introduced. Our supply will be in line with demand in Colombia, ensuring that people living with HIV have access to the medication they need.
As a company 100% dedicated to HIV, we remain committed to continue making our medicines more widely available and live our mission of leaving no person living with HIV behind.
Media contacts
For our corporate press office, email: Rachel Jaikaran
OR call +44 7823 523 755
For US-specific media enquiries,email: Audrey Abernathy
OR call +1 919 605 4521
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
